Hepatitis Market Analysis and Reports | Ireland Conference Series

Market Analysis - Hepatitis 2018

Hepatitis is an inflammatory condition of the liver caused by the hepatitis virus. The most observed types of this disease are hepatitis A, hepatitis B and hepatitis C. Globally, 350 million people are chronically infected with any one form of hepatitis and around 500,000 people die every year according to World Health Organization.

Hepatitis A is a simpler form of which does not lead to chronic infections. Patients suffering from hepatitis A recover within two months as this form is less complicated and can be prevented with vaccination.

Although hepatitis B can be prevented by vaccination, once infected, a person can develop lifelong chronic infection resulting into severe liver damage. More than 2 billion people of the global population are infected with hepatitis B. Hepatitis B patients are vulnerable to further complications related to the liver, such as: hepatocellular carcinoma (liver cancer), liver failure, and liver cirrhosis.

Hepatitis C is most dangerous of among all the types of hepatitis as 80% of the hepatitis C infected patients get chronically infected. Around 150 million people are infected with hepatitis C worldwide and 350,000 people die every year. It has a cure rate of less than 80%, which drops below 60% in some regions of the world. The low cure rate is supplemented in most regions by a lack of an effective vaccine against hepatitis C. Recent estimates find that about 215,000 people in the UK are chronically infected with hepatitis C.

The global demand for Hepatitis C drug Market is expected to reach 27.63 billion USD in 2021 at a CAGR of 17% between 2016 and 2021, which was 11.81 billion USD in 2015. Key applications of hepatitis C drug market are hospitals, private labs, public health labs, blood banks and physician offices. Hepatitis C drug market can be driven by the elements like prevalence of the infection, new productive treatments, rising government subsidizing and relatively lesser time of treatment. Hepatitis C market can be influenced by treatment costs, lack of awareness and information about HCV disease.

In the United States, 20 percent to 30 percent of people living with HIV are coinfected with HCV. Hepatitis C is common among people living with HIV. This means that about 225,000 to 330,000 people in the United States are living with both viruses. The majority of people living with hepatitis C do not know they have it. The most common route of transmission in the UK is using non-sterile needles and other equipment for injecting drugs. 90 percent of people who got HIV from injecting drugs are also infected with HCV. This is because both viruses can be spread easily through blood and blood products.

HBV therapeutics market grow from $2.4 billion in 2014 to $3.0 billion in 2024 at a compound annual growth rate (CAGR) of 2.4%.

Siemens AG, MedMira Inc., Inovio Pharmaceuticals, Inc. and Abbott Laboratories are lead players involved in the development of hepatitis diagnostics.

Gilead Sciences launched couple of drugs Harvoni ((ledipasvir/sofosbuvir) and Sovaldi (sofosbuvir) in the market for Hepatitis C which captured maximum market share and has cure rate of more than 95%. In the coming years, ongoing research on hepatitis C drug development in pharmaceutical industry is expected to increase the market growth. Due to prevalence of the disease, interest for Hepatitis C medication is expanding in Africa, Middle East, Asia Pacific and Latin America.  

Liver Associations

  • American Association for the Study of Liver Diseases (AASLD)
  • American Hepato-Pancreato-Biliary Association (AHPBA)
  • American Liver Foundation (ALF)           
  • Asian Pacific Association for the Study of the Liver (APASL)
  • British Association for the Study of the Liver (BASL)
  • British Liver Trust - National charity for adult liver disease
  • British Society of Gastroenterology
  • Canadian Association for the Study of the Liver (CASL)
  • Canadian Association of Gastroenterology
  • Canadian Liver Foundation (CLF)
  • Childhood Liver Tumour Study Group (SIOPEL) 
  • Children's Liver Disease Foundation (CLDF)
  • Euroliver Foundation
  • European Association for the Study of the Liver (EASL)
  • Gastroenterological Society of Australia
  • Hepatitis B Foundation
  • Hepatitis Foundation International          
  • Hong Kong Liver Foundation
  • Immunization Action Coalition
  • International Association for the Study of the Liver (IASL)
  • International Hepato Pancreato Biliary Association (IHPBA)
  • International Liver Transplantation Society (ILTS)
  • International Society for Digestive Surgery
  • Latin American Association for the Study of the Liver (ALEH)
  • Liver Kids Australia
  • Swiss Association for the Study of the Liver (SASL)
  • Taiwan Liver Cancer Association
  • Texas Society for Gastroenterology and Endoscopy
  • The Asian Pacific Association of Gastroenterology
  • The Asia-Pacific Primary Liver Cancer Expert Association
  • The Belgian Association for the Study of the Liver
  • The European Liver and Intestine Transplant Association
  • The European Society for Paediatric Gastroenterology Hepatology and Nutrition
  • The Korean Association for the Study of the Liver

Medical Colleges in Netherlands

  • Academic Medical Center
  • Amsterdam University College
  • Dutch Medical College B.V.
  • Erasmus MC
  • Leiden University
  • Maastricht University
  • Radboud University Nijmegen
  • The Hogeschool van Amsterdam
  • University College Roosevelt
  • University of Amsterdam
  • University of Groningen
  • Utrecht University
  • Webster University
  • Wittenborg University

Pharmaceutical Companies in Netherlands

  • Abbott B.V.
  • Accord Healthcare B.V.
  • ACE Pharmaceuticals
  • ACS Biomarker
  • Added Pharma B.V.
  • Alliance Healthcare B.V.
  • Am-pharma BV
  • Apotex Nederland BV
  • Argenx N.V.
  • Aspen Oss BV
  • Aurex B.V.
  • Avivia
  • BAP Medical
  • Basic Pharma Group
  • Bedrocan International B.V.
  • Bilthoven Biologicals
  • BioConnection BV
  • BioMarin Nederland
  • BMS Pharmaceuticals Germany Holdings B.V.
  • Chiesi Pharmaceuticals BV
  • DSM Sinochem Pharmaceuticals Netherlands B.V.
  • DuSart Pharma bv
  • Echo Pharmaceuticals B.V.
  • Eurocept Pharmaceuticals B.V.
  • Eurodrug Laboratories B.V.
  • Eurofins Medinet B.V.
  • Fagron NL BV
  • Femigin B.V.
  • Ferring BV
  • Genmab BV
  • Gilead
  • Grünenthal Group
  • GSK Company B.V.
  • Hal Allergy Group
  • Hikma Pharma Benelux B.V.
  • Holland Pharma
  • Hycult Biotech
  • Icon Clinical Research UK Ltd
  • IDA Foundation
  • IDB Holland bv
  • Interdos Pharma B.V.
  • Intravacc
  • ISA Pharmaceuticals BV
  • Janssen B.V.
  • Julius Clinical
  • Kempex Holland B.V.
  • Kernfarm B.V
  • Khondrion B.V.
  • Kiadis Pharma
  • Le Vet Pharma BV
  • Lead Pharma
  • Lilly Netherlands
  • Lundbeck B.V.
  • Meda Pharma BV
  • Medcor Pharmaceuticals B.V.
  • Medic-Aid
  • Menarini Benelux, Divisie Nederland
  • Merus Labs Netherlands B.V.
  • Micreos
  • MSD
  • Mundipharma Pharmaceuticals BV
  • Nanomi B.V.
  • Nordic Pharma B.V.
  • Norgine BV
  • Novartis
  • Novum Pharma BV
  • Osteo -Pharma BV
  • Panaxea B.V.
  • Pantex Holland BV
  • PharmaCell B.V.
  • Pharmachemie B.V.
  • Pharmamatch BV
  • Pharming Group NV
  • Prodivet pharmaceuticals S.A.
  • Roche Diagnostics Netherlands B.V.
  • Salveo pharma b.v.
  • Sun Pharmaceutical Industries (Europe) B.V.
  • Synaffix
  • Syncom B.V.
  • Takeda Nederland bv
  • Therabel Pharma Nederland B.V.
  • Tjoapack Netherlands B.V.
  • UbiQ
  • UCB
  • uniQure
  • Vifor Pharma Nederland B.V.
  • Will-Pharma B.V.
  • Ypsilon Pharma

List of Manufacturing Companies:

  • AbbVie Inc.
  • Bristol-Myers Squibb
  • Gilead Sciences
  • GlaxoSmithKline
  • Janssen Pharmaceuticals
  • Merck & Co.
  • Merck Sharp Dohme
  • Novartis
  • Roche
  • Schering
  • Three Rivers Pharma
  • Vertex Pharmaceuticals

Drug Approvals and Launches:

  • In 2012, the European Commission approved the use of Viread for the treatment of chronic HBV infection. Viread is also approved for the treatment of HIV infection. Patent expiration for Viread in USA is 2018 and 2017 in EU.
  • In December 2013, FDA approved Sovaldi for the treatment of HCV as a component of a combination antiviral treatment regimen.
  • In 2013 Janssen’s only hep c drug Olysio was approved.
  • In January 2014, European Commission approved Sovaldi for the treatment of HCV. Patent expiration for Sovaldi in USA is 2029 and 2028 in EU.
  • In October 2014, Gilead received FDA approval for Harvoni.
  • In November 2014 Gilead received European Commission approval of Harvoni, the first once-daily single tablet regimen for the treatment of HCV genotype 1 infected patients. Patent expiration for Harvoni in USA and EU is 2030.
  • In December 2014,Viekira Pak (ombitasvir/paritaprevir/ritonavir; dasabuvir) was approved by the FDA.
  • In July 2015, the FDA approved AbbVie's Technivie for use in combination with ribavirin for the treatment of adults with genotype 4 HCV infection in the United States.
  • In 2015 Technivie (ombitasvir/paritaprevir/ritonavir) was approved.
  • In 2015, Daklinza, an NS5A inhibitor was approved.
  • In January 2016, the FDA approved Zepatier for the treatment of adult patients with chronic HCV GT1 or GT4 infection, with or without ribavirin. Patent expiration for Intron A and Zepatier in USA is 2020 and 2031 respectively.
  • In 2016 Viekira XR was approved which has the same components of Viekira Pak but has simpler dosing.

Drugs in Clinical development:

  • Hepatitis B drugs are Direct-acting that target the virus and Indirect-acting that target the human host.

Direct-acting that target the virus is:

  • ARB-1467 is currently in phase II development
  • ALN-HBV is currently in preclinical trials
  • Hepbarna (BB-HB-331) is currently in preclinical trials
  • ARB-1740 is currently in preclinical trials
  • Lunar-HBV is currently in preclinical trials

These are siRNA, nucleotide drugs that interfere with and destructs the viral RNA.

  • CMX 157, a modified tenofovir drug that can get into liver cells more easily is currently in phase II development.
  • Myrcludex-B (MYR GmbH): Myrcludex B, a first-in-class drug for treatment of chronic hepatitis B (HBV) and chronic hepatitis delta (HDV) infection completed Phase 2a clinical trial in chronic hepatitis B and a pilot trial in HDV infection is ongoing.
  • Capsid Inhibitors that Interfere with viral capsid formation are:
  • Morphothiadin (GLS4) is currently in phase II development
  • NVR 3-778 is currently in phase II development
  • AIC 649 is currently in phase I development
  • JNJ56136379 is currently in phase I development
  • HBV CpAM is in preclinical trials
  • AB-423 is in preclinical trials
  • HBsAg Inhibitors  that interfere with the production of Hepatitis B surface antigen are:
  • Rep 2139 is currently in phase II development
  • Rep 2165 is currently in phase II development
  • RO7020322 (RG7834) is currently in phase I development
  • Antisense Molecules that binds to the viral mRNA to prevent it from turning into a viral protein are:
  • IONIS-HBVRx (GSK3228836) is currently in phase I development
  • IONIS-HBVLRx (GSK33389404) is currently in phase I development
  • Indirect-Acting that target human host is:
  • GS 4774 is currently in phase II development
  • INO-1800 is currently in phase I development
  • HB-110 is currently in phase I development
  • TG1050 is currently in phase I development
  • HepTcell is currently in phase I development
  • TomegaVax HBV is in preclinical trials

These drugs stimulate immunity as a potential therapy

  • Drugs that activate the innate immune system are:
  • GS 9620 is currently in Phase II development
  • RO6864018 (RG7795, ANA773) is currently in phase II development
  • SB9200 is currently in phase II development
  • Drugs that induce programmed cell death are:
  • EYP001 is currently in phase 1 development
  • CRV 431 (CPI 431-32) is currently in preclinical trials

Hepatitis C drugs

  • Samatasvir – currently in phase 1 development for genotypes 1, 2, 3 and 4, and in a phase II study with Olysio (simeprevir) in treatment-naïve patients with genotype 1b or 4.
  • AL-335 (odalasvir) – currently in a phase IIa study for genotype 1.
  • ACH-3422 and Odalasvir (ACH-3102) and Sovaprevir – currently in phase II studies in for genotype 1.
  • Odalasvir plus sofosbuvir is in phase II development for genotype 1.
  • Odalasvir, AL-335, and simeprevir in treatment-naive and treatment-experienced patients with and without cirrhosis for genotypes 1 through 6 are in a phase IIb study.
  • GS-4997 (Gilead): GS-4997 is an ASK-1 inhibitor indicated for NASH and alcoholic hepatitis is currently under Phase II stage of development.
  • GS-9674 (Gilead): GS-9674 is a FXR agonist indicated for NASH, Primary Sclerosing Cholangitis and Primary biliary cirrhosis is currently under Phase II stage of development.
  • GS-0976 (Gilead): GS-0976 is an ACC Inhibitor indicated for NASH is currently under Phase II stage of development.
  • 2878175 (Glaxosmithkline): 2878175 is a non-structural protein 5B (NS5B) polymerase inhibitor indicated for hepatitis C is currently under Phase I stage of clinical development.
  • ARO-AAT (Arrowhead): ARO-AAT is being developed to treat the liver disease associated with alpha-1 antitrypsin deficiency. It is currently under preclinical stage of development.
  • Novira therapeutics drug such as “2nd Generation Core Inhibitor” and “cccDNA” inhibitor are under discovery stage of development.
  • Merck currently has two regimens in Phase II clinical trials. One regimen is called MK-3682B, or MK-3, which includes grazoprevir, ruzasvir and uprifosbuvir.

FDA approved Drugs for HBV treatment:

  • Baraclude (entecavir)
  • Epivir HBV (lamivudine)
  • Hepsera (adefovir dipivoxil)
  • Intron A (interferon alpha-2b)
  • Pegasys (pegylated interferon)
  • Tyzeka (telbivudine)
  • Viread (tenofovir disoproxil fumarate)

FDA approved Drugs for HCV treatment:

  • CoPegus (ribavirin)
  • Daklinza (daclatasvir)
  • Epclusa (sofosbuvir, velpatasvir)
  • Harvoni (ledipasvir/sofosbuvir)
  • Incivek (telaprevir)
  • Infergen (interferon aphacon-1)
  • Olysio (simeprevir)
  • Pegintron (pegylated interferon alpha-2b)
  • Rebetol (ribavirin)
  • Roferon (interferon alpha-2a)
  • Sovaldi (sofosbuvir)
  • Technivie (ombitasvir, paritaprevir and ritonavir)
  • Victrelis (boceprevir)
  • Viekira Pak (ombitasvir, paritaprevir and ritonavir tablets co-packaged with dasabuvir tablets)
  • Zepatier (elbasvir, grazoprevir)

Companies manufacturing Liver equipment’s

  • Argon Medical devices Inc
  • Echosens
  • Humedics
  • KMC Systems

FDA approved drugs in 2017

  • On April 7, 2017, FDA approved supplemental applications for Sovaldi (sofosbuvir) and Harvoni (ledipasvir and sofosbuvir) to treat hepatitis C virus (HCV) in children ages 12 to 17.
  • On July 18, 2017, USFDA approved Vosevi to treat adults with chronic hepatitis C virus (HCV) genotypes 1-6 without cirrhosis (liver disease) or with mild cirrhosis. 
  • On August 3, 2017, FDA approved Mavyret, a fixed-dose combination of glecaprevir, a hepatitis C virus (HCV) NS3/4A protease inhibitor, and pibrentasvir, an HCV NS5A inhibitor.







Bristol-Myers Squibb

$ 1.44 Million

$ 1.31 Million

$ 1.19 Million



$ 1.05 Million

$1.10 Million

$1.18 Million



$ 2.12 Million

$ 13.86 Million

$ 9.08 Million


Vertex Pharmaceuticals

$ 24.07 Million

$ 17.98 Million

$ 610 Million


Janssen Therapeutics

$ 2.30 Million

$ 621 Million

$ 106 Million



$ 381 Millions

$ 182 Million

$ 63 Million





$ 1.75 Million



$ 10.28 Million

$ 5.27 Million

$ 4.00 Million



$ 153 Million

$ 18 Million

De minimis


Glaxo Smith Kline

$ 10.95 Million

$ 8.11 Million

$ 7,473 Million

Viekira Pak

AbbVie Inc

$ 48 Millions

$ 1.63 Million

$ 1.52 Million



Conference Series invites you to attend 6th World Congress on Hepatitis and Liver diseases (Hepatitis 2018) to be held in Amsterdam, Netherlands during April 09-11, 2018. The conference highlights the theme “Raising global awareness on screening and prevention of hepatitis”.

Hepatitis 2018 is a best platform with its well organized scientific program to the audience which includes symposiums, workshops, keynote lectures, plenary talks, panel discussions and poster sessions on latest research and technological developments in the arena as well as therapeutic aspects. The conference invites Hepatologists, Gastroenterologists, Virologists, Microbiologists, Pathologists, Oncologists, Toxicologists, Researchers, Students, Young researchers and business delegates across the globe.

Scope of the Conference

Hepatitis 2018 provides a great platform by gathering eminent professors, Researchers, Students and delegates to exchange new ideas.  The conference will cover a wide range of topics and allow participants to discuss about the management of liver diseases. Hepatitis 2018 conference consists of keynote and plenary lectures, special sessions (Workshop and Symposium), Young Researcher Forum and Poster presentations. Best poster presenters will be judged and awarded during the conference. To encourage broad participation from all over the world Conference Series Ltd is offering reduced registration fee for students.